SCHEMBL5536268

SCHEMBL5536268

O=COCc1ccc(F)c(C(F)(F)F)c1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.45
SLC6A4 P31645 1/20 0.44
PTPN7 P35236 6/20 0.43
DUSP3 P51452 6/20 0.43
USP28 Q96RU2 1/20 0.43
USP25 Q9UHP3 1/20 0.43
IDO1 P14902 2/20 0.41
NR3C2 P08235 1/20 0.39
EPHX1 P07099 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
P2RX7 Q99572 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5546553 0.87 KIF11 (0.45) IDO1P2RX7
SCHEMBL18086871 0.86 IDO1 (0.44) ARSLC6A4USP28USP25IDO1
SCHEMBL2091883 0.82 IDO1 (0.41) ARUSP28USP25IDO1EPHX1
SCHEMBL5543147 0.80 MAOB (0.45)
SCHEMBL18921944 0.80 IDO1 (0.39) SLC6A4USP28USP25IDO1
SCHEMBL30486158 0.79 PTPN7 (0.47) ARPTPN7DUSP3NR3C2EPHX1
SCHEMBL250310 0.79 PTPN7 (0.47) ARPTPN7DUSP3NR3C2EPHX1
SCHEMBL541099 0.79 IDO1 (0.47) ARSLC6A4IDO1
SCHEMBL5540437 0.78 KCNN4 (0.40)
SCHEMBL19251076 0.77 RXRA (0.46) ARSLC6A4PTPN7DUSP3USP28

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 AR 254/4885SLC6A4 4191/4885PTPN7 1363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.